Clinical Trials | December 30, 2025
Biohaven reports Phase 2 depression trial results
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is designed for patients with symptomatic moderate-to-severe or severe MR
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
Subscribe To Our Newsletter & Stay Updated
